DAY 4: Monday, June 6

Day 4 at the American Diabetes Association’s 82nd Scientific Sessions saw a wealth of quality data and talks. But I start off with Susana Patton from the Nemours Children's Health System in Jacksonville, Florida. Susana gave us a timely update on hypoglycemia risk, detection, and treatment using telemedicine – a practice that has become more widespread in recent years as we tried to remain connected with our patients through the pandemic. 

I’ve also chosen to include a talk from Roy Taylor from Newcastle University in the UK, who presented on glycemic criteria for diagnosing remission of type 2 diabetes, including some interesting temporal aspects.

Also for Day 4, Amy Mottl’s presentation in the Joint ADA/ASN Symposium, where she highlighted the rise of kidney disease in youth with type 1 diabetes and type 2 diabetes.

And finally – today’s interviews are with Robert Gabbay, ADA Chief Science and Medical Officer, and Stefano Del Prato, EASD President, who together Chaired the symposium looking at the Joint ADA/EASD statement on the Management of Hyperglycemia in Type 2 Diabetes. A number of years ago, the ADA and EASD decided it would be of great value to take a deeper dive into some areas, and developed a consensus report to provide alignment. It is not only a description of what the recommendations are, but how to implement them. Over time the initial publication has been updated, and the symposium presented the latest draft. 

We also talked with Peter Rossing, who joined us in New Orleans from the Steno Diabetes Center in Copenhagen, Denmark, to share news about the new joint statement from the ADA and KDIGO on the management of diabetes and chronic kidney disease. 

We hope you are looking forward to the last day, and encourage you to use all the networking and discussion facilities available to you during what remains of the meeting. 

Dana Dabelea, MD, PhD
ADA 2022 Highlights Editor
Denver, CO, USA

Dr. Gabbay & Del Prato 

About ADA Feedback Audio Library